Baxter

Baxter International Inc. is an American health care company with headquarters in Deerfield, Illinois. Our company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions. We have three manufacturing divisions: BioScience (producing recombinant and blood plasma proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies and other chronic and acute blood-related conditions; products for regenerative medicine; and vaccines); Medication Delivery (producing intravenous solutions and other products used in the delivery of fluids and drugs to patients, as well as inhalation anesthetics and contract manufacturing services); and Renal (providing products to treat end-stage renal disease, or irreversible kidney failure, including solutions and other products for peritoneal dialysis and hemodialysis). Baxter conducts business in more than 100 countries and operates manufacturing facilities in 27 countries and employs 48,000 people.

 

Stakeholders play an important role in Baxter’s continued success, and the company strives to take into account their varied perspectives. Baxter engages with stakeholders worldwide to share information, better understand their views on the company’s priorities, programs and performance, and determine opportunities to collaborate and to reach common goals.

 

We work with Government, Regulatory and Health Authorities throughout the world. Examples include City of Chicago, Committee for Proprietary Medicinal Products, European Medicines Valuation Agency, European Commission, European Parliament, ministries of health and environment, health and safety agencies worldwide, State of Illinois, U.S. Center for Medicare/Medicaid, U.S. Department of Agriculture, U.S. Department of Defense, U.S. Department of Health and Human Services, U.S. Department of Labor, U.S.Drug Enforcement Agency, U.S. Environmental Protection Agency and U.S. Food and Drug Administration.

 

Our channels of engagement take many forms:

 

  • Representation on advisory committees
  • Meetings, conferences and collaborations
  • Communication studies that demonstrate health and economic benefits of Baxter’s products
  • Promotion of national sustainability programs/initiatives.
  • Lobbying activities

 

Baxter supports legislation/regulation that aligns with the company’s business and sustainability objectives.

Many legislative issues affect Baxter’s business – reimbursement, tax, trade and a variety of regulatory concerns. Baxter’s Government Affairs and Public Policy (GAPP) team works with lawmakers, governments and policymakers around the globe to support patient access to the company’s life-saving therapies, increase understanding of the benefits of those therapies, address barriers to care and explore possible solutions. This work involves dealing directly with governments to improve the regulatory environment and reimbursement structure for Baxter’s therapies, and collaborating with clinicians, non-governmental organizations and patient groups on coordinated efforts to increase access to care for millions of patients worldwide.

 

The Public Policy Committee of Baxter’s Board of Directors oversees Baxter’s government affairs activities. The committee reviews Baxter’s positions on pending legislation and political advocacy activities.

 

Healthcare Reform

Healthcare reform efforts around the world seek to expand access to healthcare and reduce costs. In the United States, the Patient Protection and Affordable Care Act, signed into law in March 2010, contains several provisions that impact Baxter’s business. Most significant are increased rebates to state Medicaid programs for some of the company’s drugs and biologics, and expansion of the 340B Drug Pricing Program, which raises the potential number of healthcare providers that qualify for discounts on drugs provided to Medicaid patients. Baxter also will be required to pay a tax on the sale of its pharmaceutical products to the government beginning in 2011, and on certain medical devices beginning in 2013.

 

Baxter’s U.S. GAPP organization was closely involved in the healthcare reform debate in Congress and its potential implications for Baxter. On parts of the legislation, the company worked with biotechnology and other industry groups to educate policymakers regarding potential impacts on manufacturers, their customers and their patients. Because of the unique nature of Baxter’s products and how they are used and administered (largely infused or injected to treat rare, life-threatening chronic diseases) compared to traditional pharmaceutical products, it was particularly important for Baxter to attempt to mitigate any unintended negative consequences for its patients.

 

In 2010, Baxter supported efforts to expand access to health insurance for patients with high-cost chronic diseases, such as hemophilia, through high-risk pools. The Patient Protection and Affordable Care Act provides federal funding for such pools to cover patients with medical conditions who might otherwise be denied coverage by private insurers until 2014, when the law will prohibit insurers from refusing coverage to patients with pre-existing conditions. While risk pools will be available in every state, the mechanisms for coverage will vary and are still taking shape. Baxter is working to help ensure these pools will accommodate patients with rare chronic diseases without assessing unreasonably high co-pays or premiums.

 

To further assist patients and customers in implementing healthcare reform at the state level, Baxter created a 24/7 access Internet tool that has been added to the company’s patient and customer-focused websites . These sites provide specific information for patients living with hemophilia and end-stage renal disease, as well as hospital customers:

Canada Experience Helps Shape Taiwan Policy for Treating ESRD Patients

As a leading provider of products for peritoneal dialysis (PD), the predominant home-dialysis therapy for patients with end-stage renal disease (ESRD), or irreversible kidney failure, Baxter works with governments around the world to increase access to PD. This can provide cost and quality-of-life benefits compared to in-center dialysis.

 

In 2010, the Taiwan government was studying policy options to most effectively treat its ESRD patients. To support an evidence-based dialogue on this issue, Baxter’s GAPP organization in Taiwan convened a roundtable discussion for representatives of the Ministry of Health and the Bureau of National Health Insurance. Drawing on the experience in Ontario, Canada, the Taiwanese Department of Health adopted a similar policy to increase the use of PD.

Increasing Access to Hemophilia Therapy

In China, most people with hemophilia do not receive adequate treatment. In fact, most are not even diagnosed. Baxter is lending its expertise in hemophilia therapy to the China Ministry of Health in support of a nationwide initiative to improve the country’s hemophilia diagnosis and treatment capabilities. The program includes the creation of a nationwide hemophilia patient registry, hemophilia management centers and the improvement of standards for hemophilia diagnosis and treatment. In 2010, China established its first hemophilia patient registry, with an initial 8,000 patients.

 

In Mexico, Baxter also played a supportive role in a government initiative to increase access to hemophilia care. The company worked with the Mexican Hemophilia Federation to advocate for greater hemophilia therapy coverage in the Catastrophic Disease category of Mexico’s Seguro Popular national insurance program. Starting in 2011, Seguro Popular began covering treatment for children under 10 years old with hemophilia A or von Willebrand disease. The program already covered children over 10 years old, who will continue to be covered for their hemophilia treatment.

 

Influencing Infection Control Guidelines in Australia

Healthcare-associated infections (HAIs), also known as nosocomial infections, are infections that patients get while in a hospital or other healthcare facility. HAIs lead to increased treatment costs and lengths of stay. HAIs can be prevented through various means, such as rigorous hand hygiene and aseptic techniques. Certain healthcare technologies and products also can play a role. Closed intravenous (IV) medication delivery systems and premixed products, for example, have a proven record of reducing bloodstream infections, a common type of HAI.

 

In 2010, Australia’s National Health and Medical Research Council, and the Australian Commission on Quality and Safety in Healthcare, jointly released the official Australian Guidelines for the Prevention and Control of Infection in Healthcare. Baxter’s GAPP organization in Australia provided evidence-based input into the draft guidelines. This included roundtable discussions with healthcare professionals and government representatives, visits by key stakeholders to Baxter’s manufacturing facility in Sydney where the company produces closed IV delivery systems for Australian hospitals, and publication of various white papers on reducing HAIs. The final guidelines were published in October, outlining standard precautions and steps, including standard practices for use of closed IV delivery systems to prevent and reduce infections.

 

Baxter and its employees also lend their voices to discussion of industry issues that affect Baxter and its customers through membership in many professional, industry and business organizations, covering a variety of geographic areas, diseases, markets and topics.

 

Affiliations and Memberships

Baxter and its employees engage with many professional, industry and business organizations,  covering a variety of geographic areas, diseases, markets and sustainability issues. By participating in these groups, Baxter can expand its influence, help raise industry standards, share and learn best practices, and advance discussions within and beyond the healthcare industry. Forming relationships with these associations helps Baxter engage with and meet the ongoing needs of relevant stakeholders.

Baxter believes that membership in these organizations is generally consistent with the company’s interests as well as those of its shareholders, customers and patients. Even when Baxter does not share all of the views of one of these organizations, it believes that membership is worthwhile because such organizations encourage dialogue on important policy issues and help to move the industry to a consensus on such issues.

 

Advocacy Coalitions

  • Alliance for Work-Life Progress
  • Boston College Center for Corporate Citizenship
  • Boston College Center for Work & Family
  • Catalyst
  • Center for Companies That Care
  • Corporate Voices for Working Families
  • National Safety Council
  • Partnership for Quality Medical Donations
  • Pew Center on Global Climate Change

 

Environmental and Sustainability Organizations

  • Business for Social Responsibility
  • Canadian Business for Social Responsibility
  • Ceres
  • Chicago Climate Exchange (acquired by IntercontinentalExchange in 2010)
  • Global Reporting Initiative
  • National Environmental Education Foundation
  • SustainAbility Engaging Stakeholders Program

 

Industry Organizations

  • AdvaMed
  • Assobiomedica (Italy)
  • BIOTECanada
  • Biotechnology Industry Organization
  • EucoMed
  • EuropaBio
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • European Organization for Packaging and the Environment (EUROPEN)
  • European Vaccine Manufacturers
  • Hemophilia Federation of America
  • Irish Business & Employers Confederation (IBEC) – Health & Safety Policy Committee
  • Institute for Supply Management
  • MEDEC
  • Plasma Protein Therapeutics Association
  • Rx-360 (International Pharmaceutical Supply Chain Consortium)
  • US-ASEAN Business Council
  • VCI Association of Chemical Industry (Germany)

 

Patient Organizations

  • Alpha-1 Foundation
  • American Association of Kidney Patients
  • Dialysis Patient Citizens
  • Immune Deficiency Foundation
  • Hemophilia Federation of America
  • International Society of Peritoneal Dialysis North American Chapter
  • Jeffrey Modell Foundation
  • National Hemophilia Foundation
  • National Kidney Foundation
  • The Oley Foundation
  • World Federation of Hemophilia

 

Professional Organizations

  • American Association of Critical-Care Nurses
  • American Nephrology Nurses Association
  • American Society of Anesthesiologists
  • American Society of Health-System Pharmacists
  • American Society of Nephrology
  • American Society of Parenteral and Enteral Nutrition
  • The Auditing Roundtable
  • Board Source
  • Corporate Executive Board Compliance and Ethics Leadership Council
  • Council on Foundations
  • Ethics & Compliance Officer Association
  • Ethisphere Council
  • Grantmakers in Health
  • International Society of Nephrology
  • Institute of Environmental Management and Assessment (IEMA)
  • Institute of Occupational Safety and Health (IOSH)
  • Institute for Safe Medicine Practices
  • Institute for Supply Management
  • NAEM (formerly National Association for Environmental Management)
  • National Minority Supplier Development Council, Inc.
  • Renal Physicians Association
  • Society of Corporate Compliance and Ethics (SCCE)
  • Women’s Economic Development Organization

 

Regional and Local Organizations

  • Asociación Colombiana de Hospitales y Clínicas (ACHC)
  • Asociación Venezolana de Equipos Médicos (AVEDEM)
  • Associação Brasileira dos Importadores de Equipamentos, Produtos e Suprimentos Médicos-Hospitalares (Abimed) (Brazil)
  • Australian and New Zealand Society of Nephrology
  • BioCrossroads (Indiana)
  • Cámara Industria Farmacéutica en Chile (ASILFA) (Chile)
  • Campaign for Greener Healthcare – Green Nephrology Group
  • Canadian College of Health Service Executives
  • Canadian Patient Safety Institute
  • Chicago United
  • The Commercial Club of Chicago
  • Donors Forum (Illinois)
  • Illinois Biotechnology Industry Organization
  • Green Building Council Italia
  • Japan Pharmaceutical Manufacturers Association
  • Korea Pharmaceutical Manufacturers Association
  • National Center for Asia-Pacific Economic Cooperation
  • Pharmanet
  • Puerto Rico Manufacturers Association
  • Sociedad Argentina de Farmacia y Bioquímica (SAFIBY)